A 40-year-old patient came with Steven Johnson Syndrome (SJS) like mucositis involving the ocular and oral mucosae. She had a preceding history of fever with cough for which she had been given tablet Paracetamol and some undocumented medications by a general practitioner. This treatment was continued for 5 days, following which the patient developed red painful eyes. A day following this, she developed painful swelling and ulceration ofthe lips and oral cavity, thereby causing difficulty in chewing and swallowing leading to reduced oral intake. On examination, there was bilateral congested conjunctivaealong with erosions and crusting over the lower lip and intra-oral erosions involving bilateral buccal mucosae and visible portion of pharynx \[[Figure 1](#F1){ref-type="fig"}\]. We considered differential diagnoses of SJS and Erythema multiforme (EM) in view of the morphology of oral/ocular lesions, drug intake history and corroborative chronology. However, there was no skin involvement at presentation, which was on the 5^th^ day of development of oral and ocular involvement. A chest radiograph showed bulky hilum \[[Figure 2](#F2){ref-type="fig"}\]. In addition, there was leucocytosis (12000/mm^3^), neutrophilia, elevated C-reactive protein (\>10 mg/L) and erythrocyte sedimentation rate (35 mm/hour). *Mycoplasma pneumonia* IgM serology was done considering the respiratory symptoms at the outset this came out to be positive at 17 units (normal = \<10). A final diagnosis of *Mycoplasma pneumoniae* induced rash and mucositis (MIRM) sine rash was made. The patient was treated with supportive measures and azithromycin for 5 days. She recovered fully within a week and was then discharged.
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MIRM is an uncommon condition, with most reports being in the pediatric age group.\[[@ref1]\] In the past, the condition was labelled as atypical SJS, incomplete SJS or Fuch\'s syndrome. Mucositis, the most prominent and consistent sign of MIRM, follows respiratory symptoms usually by a period of few days to a week.\[[@ref2]\] Oral mucosa is most commonly involved (94%) followed by ocular (82%) and urogenital mucosa (63%).\[[@ref3]\] Canavan *et al.*\[[@ref3]\] classified MIRM into 3 types depending on the pattern of cutaneous rash: *Classic MIRM* with sparse skin involvement; *MIRM sine rash* with no significant skin involvement; and *Severe MIRM* with widespread skin involvement. The precise pathomechanism is still unknown, but thought to involve either direct cytotoxicity or cross-reacting autoantibodies aimed at the glycolipidantigens of *M pneumonia*e.\[[@ref4]\] The cutaneous involvement is akin to SJS/TEN with vesiculobullous lesions, targetoid plaques, papules, macules and morbilliform eruptions.

The skin involvement is however mostly sparse (47%) or absent (34%) and less commonly moderate (19%).\[[@ref3]\] Diagnosis requires a high index of suspicion in view of clinical similarity to EM/SJS/TEN.\[[@ref5]\] A misdiagnosis has both short-term and long-term implications. Apart from the more frequent pulmonary disease, which is due to the *M.pneumoniae* infection itself, MIRM is a much milder disease than SJS/TEN, with rare mortality. Empiric antibiotic therapy is mostly given but probably does not shorten the course of the disease.\[[@ref1]\] Limited data suggests that antibiotics instituted early in the course of atypical pneumonia doesnot decrease the incidence of MIRM.\[[@ref4]\] Immunomodulatory/immunosuppressive treatment as given for SJS/TEN is generally not required.\[[@ref3]\] Further wrongful implication of drugs leads to unnecessary life-long avoidance.
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